{"slug":"tirzepatide-ibd","verification":{"valid":true,"entries":4,"head":"9328953bb7d839fb95ab27ac5455f0e01089bf203896b56b63531e63c52ddd19"},"count":4,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39516435/","title":"Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Patients With Inflammatory Bowel Disease","quote":"The study included 36 patients with IBD... BMI significantly decreased from 34.0... to 31.0... Total body weight (TBW) significantly decreased by a median of 8.15 kg...","summary":"Single-center observational cohort on semaglutide/tirzepatide in non-diabetic IBD patients.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:46:02.549Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"6d29cad17dc75db9a5e6456ffbda95ef0b6ac9c776ed3a78f1627eae83406f04"},{"id":"s2","type":"medical","url":"https://journals.lww.com/ajg/fulltext/2025/10002/s1890_safety_and_weight_loss_outcomes_of.1891.aspx","title":"Safety and Weight Loss Outcomes of Tirzepatide in Obesity Patients With Inflammatory Bowel Disease","quote":"obesity patients with IBD treated with tirzepatide experience similar weight loss outcomes but significantly more side effects, particularly gastrointestinal symptoms","summary":"Retrospective matched-control study comparing IBD and non-IBD tirzepatide users.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:46:02.549Z","link_status":"ok","quote_status":"verified","prev":"6d29cad17dc75db9a5e6456ffbda95ef0b6ac9c776ed3a78f1627eae83406f04","hash":"21ce7ec758d8174b3a300f957b7d6ff802bcdcf115a032ccb9e7ce2dcea3250b"},{"id":"s3","type":"review","url":"https://www.mdpi.com/1467-3045/47/5/383","title":"Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Disease","quote":"GLP-1 RAs appear to lessen the intestinal inflammatory burden by enhancing intestinal epithelial barrier features and modulating the gut microbiota.","summary":"Review covering mechanistic data from preclinical models.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:46:02.549Z","link_status":"http_403","quote_status":"unverified","prev":"21ce7ec758d8174b3a300f957b7d6ff802bcdcf115a032ccb9e7ce2dcea3250b","hash":"de455064f75dea01b055d53b9856ec79b9841bdf8a47c657dd5140123794e66a"},{"id":"s4","type":"clinical_trial","url":"https://trials.lilly.com/en-US/trial/600156","title":"Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","quote":"evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide","summary":"Ongoing Phase 3 trial in Crohn's with obesity.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:46:02.549Z","link_status":"ok","quote_status":"unverified","prev":"de455064f75dea01b055d53b9856ec79b9841bdf8a47c657dd5140123794e66a","hash":"9328953bb7d839fb95ab27ac5455f0e01089bf203896b56b63531e63c52ddd19"}]}